Award notice Supplies

Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios Activos Riociguat, Doravirina, Letermovir, Sotatercept, Ceftolozano Sulfato/Tazobactam Sodico).

Notice published in Spanish. The AI analysis summarises it for you in your language.

Official notice and documents

Public buyer: Servicio Cántabro de Salud
Santander
Place of performance: Santander
Estimated value: €15,761,786 excl. VAT
Bids received: 1
Form: Framework agreement
Multi-year contract: the buyer places orders as needs arise.
Procedure: Negotiated procedure without prior publication
The buyer consulted a few companies directly: it is no longer possible to take part.
Publication: 8 September 2026
Notice language: Spanish

AI analysis: go for it or not?

Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.

Create my free account

Unlimited analyses during the 14-day Pro trial, no card needed.

Description

Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios Activos Riociguat, Doravirina, Letermovir, Sotatercept, Ceftolozano Sulfato/Tazobactam Sodico).

Awarded to

MERCK SHARP Y DOHME DE ESPAÑA, S.A.

4 lots

Lote 2. Pifeltro (Doravirina)
Lote 3. Prevymis (Letermovir)
Lote 4. Winrevair (Sotatercept)
Lote 5. Zerbaxa (Ceftolozano Sulfato/Tazobactam Sodico)

CPV codes

European codes that classify what the contract is about. They are how we find the tenders for your trade.

33600000

Winning prices for comparable contracts

A quarter below: €350,000
Median: €846,164
A quarter above: €2,267,877

Amounts awarded (excl. VAT) over the last 3 years for 265 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.

Similar contracts already awarded

Contract	Winner	Amount
Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud Servicio Cántabro de Salud · 20 October 2026	Gilead Sciences S.L.	–
Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios activos Brodalumab, Delgocitinib, Tralokinumab, Spesolimab). Servicio Cántabro de Salud · 15 October 2026	LABORATORIOS LEO PHARMA, S.A.	–
Acuerdo Marco para el suministro de medicamentos exclusivos para el Hospital Universitario Marqués de Valdecilla. Servicio Cántabro de Salud · 25 September 2026	GILEAD SCIENCES, S.L. NOVARTIS FARMACEUTICA, S.A. BRISTOL MYERS SQUIBB, S.A.U JANSSEN CILAG, S.A. VERTEX PHARMACEUTICALS SPAIN, S.L.	€82,436,694
Acuerdo Marco para el suministro de medicamentos sin competencia para los hospitales del Servicio Cántabro de Salud (Principios activos Luspatercept, Mavacamten, Fedratinib, Belatacept, Abatacept, Deucravacitinib, Ipilimumab, Ozanimod). Servicio Cántabro de Salud · 24 September 2026	BRISTOL-MYERS SQUIBB, S.A.	–
Acuerdo Marco para el Suministro de Medicamentos sin competencia para los Hospitales del Servicio Cántabro de Salud (Principios activos Blinatumomab, Carfilzomib, Sotorasib, Romiplostim, Etelcalcetida hidrocloruro, Evolocumab, Inebilizumab, panitumumab) Servicio Cántabro de Salud · 24 September 2026	AMGEN S.A.	–

Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 618975-2026.